KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization - Total (2016 - 2021)

Arbutus Biopharma's Depreciation & Amortization - Total history spans 9 years, with the latest figure at $447000.0 for Q3 2021.

  • For Q3 2021, Depreciation & Amortization - Total fell 8.78% year-over-year to $447000.0; the TTM value through Jun 2022 reached $447000.0, down 75.92%, while the annual FY2020 figure was $2.0 million, 2.47% down from the prior year.
  • Depreciation & Amortization - Total for Q3 2021 was $447000.0 at Arbutus Biopharma, up from $436000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $620000.0 in Q4 2017 and bottomed at $334000.0 in Q1 2017.
  • The 5-year median for Depreciation & Amortization - Total is $500000.0 (2020), against an average of $501705.9.
  • The largest annual shift saw Depreciation & Amortization - Total soared 103.78% in 2017 before it dropped 16.19% in 2018.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $620000.0 in 2017, then dropped by 19.84% to $497000.0 in 2018, then increased by 2.01% to $507000.0 in 2019, then decreased by 3.94% to $487000.0 in 2020, then fell by 8.21% to $447000.0 in 2021.
  • Per Business Quant, the three most recent readings for ABUS's Depreciation & Amortization - Total are $447000.0 (Q3 2021), $436000.0 (Q2 2021), and $443000.0 (Q1 2021).